On Tuesday, shares of Australia based manufacturer of the best-selling ear implant, all over the world, Cochlear Ltd., were observed to tumble more than 5%., having a strong influence from a voluntary recall anticipated to cost around A$150 million. The 29-years-old company has a name for its bionic ear that was devised by a renowned researcher of Melbourne, Graeme Clark.

While delivering a speech during the annual meeting of the company organized in Sydney, the Chairman of the Cochlear, Rick Holliday-Smith, estimated that the recall will account between A$130 million-to-A$150 million, a significant deviation as compared to UBS AG’s suggested figure, A$100 million. Cochlear is looking forward to keep it level stable at A$1.20-a-share dividend, added Mr. Holliday-Smith.

Further, the Chairman had claimed that the company has a reputation and said: “We regret the difficulties it has created for so many of our stakeholders, but it was the right thing to do especially when our primary consideration is always the welfare of our recipients”.

However, the shares of the company have faced an embarrassing situation when lost around 26% of their value in a short span of time, since September 11, soon after the announcement regarding a recall for its Nucleus CI500 range. The company authorities have decided to recall as acknowledged a number of failure cases of CI512 units.

As per the reports, the company ended on a lower position at A$53.54 on the Australian stock exchange after a downfall of 1.8%. Experts have observed it as largest decrease since October 4.

During the last financial year, the company has credited to reflect revenues of A$809 million where the United States have contributed for around 43% sales, alone, whereas the European and Asian market have contributed with a
40% and 17 % sale, respectively.